CGON - Company ID 0001991792
CG Oncology, Inc. trades as CGON and has a market capitalization of $6.48 B, making it the #1231 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $4.04M, up 254.7% from the prior year and net income of -$161.00M. This page tracks CG Oncology, Inc. through 189 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -23827.0% to -3985.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-08 |
| Major company event | 8-K | 2026-05-08 |
| Annual report to shareholders | ARS | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award | CG Oncology
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | CG Oncology
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC | CG Oncology
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | CG Oncology
CG Oncology to Present at Upcoming Investor Conferences in May | CG Oncology
The largest companies sharing CG Oncology, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
CG Oncology, Inc. (CGON) has a market capitalization of $6.48 B as of 2026-07-09, ranking #1231 among US-listed companies.
CG Oncology, Inc. reported revenue of $4.04M for fiscal year 2025, an increase of 254.7% year over year.
In its latest fiscal year CG Oncology, Inc. reported a net loss of $161.00M.